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Introduction: Resistance to thyroid hormone is a rare syndrome, where although the level of thyroid hormone is
elevated, the level of thyroid stimulating hormone is not suppressed. The patient in our case report is, to the best
of our knowledge, the first with this syndrome identified in Oman.
Case presentation: In one Omani family, a 15-year-old girl of Arabian origin was pre-diagnosed with resistance to
thyroid hormone. Blood sample was collected and deoxyribonucleic acid was isolated for molecular genetic testing.
The results revealed a rare mutation A268G in the gene for thyroid hormone receptor beta. We believe that this
mutation is the cause of the pathology in our patient.
Conclusion: We report the presence of a rare mutation in the thyroid hormone receptor beta gene for the first time
in the Omani population. Due to the rates of consanguinity being high among the Omani population, we are
aiming to screen our patient’s family members and provide genetic counseling.
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Resistance to thyroid hormone (RTH) is a rare disorder
characterized by reduced tissue response to free thyroxine
(FT4) hormone. RTH is an inherited disorder characte-
rized by variable tissue hyposensitivity to 3,5,3′-l-triiodo-
thyronine (T3), with persistent elevation of circulating free
T3 (FT3) and FT4 levels, along with non-suppressed serum
thyrotropin (TSH) [1,2]. Sporadic cases are common, but
recessive cases are rare [1]. This syndrome was initially
identified by Refetoff and colleagues, and since then 1000
cases have been identified from 339 families [2]. In 2008,
Refetoff et al. reported more than 2000 individuals with
RTH belonging to about 500 families [3]. RTH is associ-
ated with mutations in the thyroid hormone receptor beta
(THRβ) gene; the THRβ protein is a nuclear hormone re-
ceptor for T3. Mutations in THRβ are associated with thy-
roid hormone resistance. The mode of inheritance can be
autosomal dominant or recessive. The majority of patients
are heterozygous for the mutant THRβ allele, consistent* Correspondence: aouhtit@squ.edu.om
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reproduction in any medium, provided the orwith the autosomal dominant pattern of inheritance [3].
Mutant THRβs can interfere with the function of the wild-
type receptor in a dominant negative manner [4]. Lee
et al. reported that at least 137 different THRβ mutations
have been associated with RTH syndrome, affecting more
than 40,000 people worldwide [5]. In our study, screening
by direct sequencing analysis revealed a rare mutation
(A268G) in the THRβ gene in a patient with RTH.
Case presentation
A 15-year-old Omani girl of Arabian origin had pre-
sented with episodic palpitations since birth. At age 11
an electrocardiogram showed sinus tachycardia, whereas
an echocardiogram was normal. Four years later, she
presented with the episodic palpitations associated with
mild dizziness. Her past medical history was normal and
she reported no similar problem in any member of her
family. A clinical examination showed a normal-looking
girl with normal growth for her age. There was no evi-
dence of mental retardation, but her parents reported
that she had low performance at school. Her blood pres-
sure was 124/59mmHg with a pulse rate of 108beats/min.
She was not pale and her thyroid gland was not enlarged.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gram showed tachycardia with a few ventricular ectopics
and an echocardiogram was once again normal.
A complete blood count was performed and her he-
moglobin level was normal. Her C-reactive protein level
was 97mg/L (normal range: 0 to 8mg/L), electrolytes
were normal, potassium was 3.8mmol/L (normal range:
3.5 to 5.1mmol/L), sodium 139mol/L (normal range: 135
to 145mol/L), creatinine 33μmol/L (normal range: 29 to
56μmol/L), and urea 3.0mmol/L (normal range: 2.1 to
7.1mmol/L). Her FT4 level was 30.7pmol/L (normal range:
8.7 to 13.6pmol/L), FT3 9.0pmol/L (normal range: 3.8
to 6.0pmol/L), TSH 1.56mIU/L (normal range: 0.60 to
3.70mIU/L), thyroid antibodies (anti-thyroglobulin and
antimicrosomal antibodies) 1IU/mL (normal range: 0 to
50IU/mL) and thyroglobulin 13μg/L (normal range: 3 to
30μg/L). Her thyroglobulin antibody level was <0.9IU/mL
(normal range: 0.0 to 4.0IU/mL) and anti-thyroid re-
ceptor antibody level was 0.30UI/L (normal range: 0.00 to
1.50UI/l). A thyroid ultrasound showed altered echo tex-
ture with normal vascular flow on Doppler study. Tiny
cystic areas of 2mm to 4mm were seen on both lobes.
There were no significant nodules in her thyroid gland,
and no lymphadenopathy was detected in her neck. A
technetium-99m thyroid scan showed a total uptake of
3.2% (normal uptake: 1% to 4%) seen on both lobes, and
no cold nodules were observed. Her prolactin level was
727mIU/L (normal range: 71 to 566mIU/L). Magnetic res-
onance imaging scan of the pituitary gland and brain
showed that both her pituitary gland and brain were nor-
mal in size and morphology.
Blood samples were collected from our patient and
her deoxyribonucleic acid (DNA) was isolated. The sam-
ples were sent to an accredited laboratory in the Depart-
ment of Clinical Genetics at the University of Amsterdam,
Netherlands. Direct sequencing analysis of the full THRβ
gene was performed. The results revealed the presence of
heterozygous mutation c.803C >G in THRβ. This nucleo-
tide change results in the amino acid change p.Ala268Gly
in THRβ. Hence, this mutation indicates that our patient
was most likely affected with RTH. We therefore treated
her with beta-blockers to control her tachycardia.
Discussion
RTH is characterized by tissue hyposensitivity to ele-
vated levels of FT3 and FT4 in association with un-
suppressed serum thyrotropin (TSH) [6]. Patients with
congenital RTH can be clinically euthyroid, but often
show increased levels of FT4 and FT3 with unsuppressed
TSH [7]. In our patient, the elevated levels of thyroid
hormones (FT3 and FT4) with normal levels of TSH, ex-
clusion of a pituitary tumor by magnetic resonance im-
aging and the presence of a rare mutation, p.Ala268Gly,
in THRβ support the diagnosis of RTH. The DNAanalysis of our patient showed the presence of a hetero-
zygous mutation c.803C > G in THRβ. An alpha subunit
to TSH ratio, which would give more support to the
diagnosis, will be calculated in our patient during the
screening of her family. Rivolta et al. reported that 85%
of patients were heterozygous for the mutant THRβ
allele, consistent with the autosomal dominant mode of
inheritance [6]. In our patient, the c.803C > G nucleotide
change, resulting in the amino acid change p.A268G, al-
tered the highly conserved amino acid THRβ. This mu-
tation was not detected in 60 other index patients and
13,000 control alleles in the indexed laboratory. This
rare mutation has been previously described only in a
four-generation family with RTH [8] and in one South
American patient [6].
The incidence of RTH is one in 40,000 [9]. The clinical
presentation of this syndrome is variable. Some individ-
uals tend to be normal and the syndrome is detected
only on routine investigations, whereas others may dis-
play features such as goiter, hyper- and hypothyroidism,
delayed bone maturation, short stature and attention
deficit hyperactive disorder [10]. Goiter is the most com-
mon finding, reported in 66% to 95% of patients [11].
Our patient had no goiter. According to the clinical
presentation, this syndrome has been divided into two
entities; generalized type (GRTH) and pituitary type
(PRTH). Patients with RTH who appear normal or hy-
pothyroid are considered to have GRTH, and those with
thyrotoxic clinical presentation are considered to have
PRTH [12]. Accordingly, we would classify our patient
as having PRTH, because of her sinus tachycardia. One
of the most important reasons for recognizing RTH is
that its management is different from other types of thy-
roid dysfunction. Also, it is important to distinguish
GRTH from PRTH using clinical criteria as the manage-
ment of these two types differ. Patients with PRTH
should not be treated with anti-thyroid drugs, as any
reduction of the thyroid hormone will aggravate the
symptoms, reduce growth and increase the goiter size.
Patients with this type, similar to our patient, are usually
the most difficult to treat. Patients with GRTH can
benefit from thyroxin administration, since it reduces
TSH level and the goiter [5].
The alpha subunit of the TSH (α-GSU/TSH) was not
measured in our patient, which is considered as a limita-
tion of this case report, because of non-availability of the
test. While the main difference between patients with
TSH-producing pituitary tumors (TSHomas) and RTH
is the presence of symptoms of hyperthyroidism; a mi-
nority of patients with RTH might display signs of hy-
perthyroidism involving some organs and not others,
known as PRTH [13]. Nevertheless, the differential diag-
nosis between these forms of RTH and TSHomas may
be difficult, and elevated α-GSU concentrations or high
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ingly, similar biochemical data in relatives favors RTH.
Therefore, α-GSU concentrations or high α-GSU/TSH
molar ratio will be measured in the next study, which will
include our patient and other members of her family.Conclusion
We report the presence of a rare mutation in the THRβ
gene for what we believe to be the first time in the
Omani population. Because of high rates of consanguin-
ity in this population, screening of a large number of our
patient’s family members is required to identify similar
or different types of gene mutations. On the basis of the
result, appropriate treatment related to the type of clinical
presentations can be provided to the relatives. Futher-
more, genetic counseling can also be provided to those
who intend to have consanguineous unions and can help
in prevention of the disease.Consent
Written informed consent was obtained from the pa-
tient’s guardian for publication of this case report. A
copy of the written consent is available for review by the
Editor-in-Chief of this journal.
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